For a patient with an acute ischemic stroke and NIHSS ≤3 who can be treated within 24 hours, should I start dual antiplatelet therapy with clopidogrel 75 mg plus aspirin 75 mg daily for 21 days?

Dual Antiplatelet Therapy for Acute Minor Stroke (NIHSS ≤3) Within 24 Hours

Yes, you should start dual antiplatelet therapy with clopidogrel plus aspirin for exactly 21 days in this patient, then transition to single antiplatelet therapy indefinitely. This recommendation is supported by the highest-quality evidence from pooled analysis of two large randomized controlled trials (CHANCE and POINT) involving over 10,000 patients. 1, 2, 3

Patient Eligibility Confirmation

Before initiating therapy, confirm all of the following criteria are met:

• Stroke severity: NIHSS score 0–3 (minor stroke) 1, 2
• Timing: Symptom onset within 24 hours (ideally within 12 hours for maximum benefit) 1, 2
• Imaging: CT or MRI has excluded intracranial hemorrhage 1, 2
• Stroke mechanism: Non-cardioembolic origin (no atrial fibrillation or other cardioembolic source identified) 1, 2
• Thrombolysis status: Patient did not receive IV alteplase, OR if alteplase was given, at least 24 hours have elapsed with repeat imaging confirming no hemorrhagic transformation 1

Loading Dose Protocol (Day 1)

Administer immediately after confirming eligibility:

• Clopidogrel: 300 mg loading dose (acceptable range 300–600 mg; the 300 mg dose from CHANCE trial may carry modestly lower bleeding risk) 1, 2
• Aspirin: 160–325 mg loading dose (non-enteric coated for faster onset) 1, 2

Maintenance Phase (Days 2–21)

Continue dual therapy for exactly 21 days total:

• Clopidogrel: 75 mg once daily 1, 2
• Aspirin: 75–100 mg once daily 1, 2

Critical timing note: The benefit of dual antiplatelet therapy is confined to the first 21 days after the index event, with most stroke prevention occurring in the first week. 1, 3 Extending beyond 21–30 days significantly increases major hemorrhage risk (hazard ratio 2.22–2.32) without additional stroke-prevention benefit. 1, 4

Transition to Long-Term Therapy (Day 22 Onward)

After exactly 21 days, discontinue one agent and continue single antiplatelet therapy indefinitely:

• First-line option: Aspirin 75–100 mg daily 1, 2
• Alternative (if aspirin intolerant): Clopidogrel 75 mg daily 1
• Alternative regimen: Aspirin 25 mg plus extended-release dipyridamole 200 mg twice daily 1

Evidence Supporting This Recommendation

The pooled analysis of CHANCE and POINT trials (10,051 patients) demonstrated that dual antiplatelet therapy:

• Reduces major ischemic events at 90 days from 9.1% to 6.5% (hazard ratio 0.70; 95% CI 0.61–0.81; P < 0.001) 3
• Greatest benefit in first 21 days: reduces stroke from 7.8% to 5.2% (hazard ratio 0.66; 95% CI 0.56–0.77; P < 0.001) 3
• No benefit from day 22 to day 90: hazard ratio 0.89 (95% CI 0.79–1.02) 1
• Number needed to treat: 67–91 patients to prevent one stroke 1

The one-year follow-up of the CHANCE trial confirmed that the early benefit persists long-term, with stroke occurring in 10.6% of the dual therapy group versus 14.0% in the aspirin-alone group (hazard ratio 0.78; 95% CI 0.65–0.93; P = 0.006). 5

Safety Profile and Bleeding Risk

• Major hemorrhage risk: Increases modestly with dual therapy (RR 1.88–1.90) but absolute risk remains low 2, 6
• Number needed to harm: Approximately 113–258 for major bleeding 1, 7
• Moderate or severe bleeding: 0.9% with dual therapy versus 0.4% with aspirin alone 6
• Intracranial hemorrhage: RR 1.55 (95% CI 1.20–2.01), but confined to long-duration therapy beyond 21 days 7

Consider gastroprotection with a proton pump inhibitor if the patient has gastrointestinal bleeding risk factors. 2, 4

Common Pitfalls to Avoid

• Do not delay initiation beyond 24 hours when eligibility criteria are met; efficacy is time-dependent with maximum benefit when started within 12–24 hours 1, 2
• Do not extend dual therapy beyond 21–30 days unless a separate cardiac indication exists (e.g., recent drug-eluting stent), as bleeding risk outweighs benefit 1, 2, 4
• Do not use dual antiplatelet therapy as a substitute for thrombolysis or thrombectomy in eligible patients 1, 2
• Do not use enteric-coated aspirin for the loading dose due to slower onset of action 1, 2
• Do not use ticagrelor instead of clopidogrel for this indication, as it is not recommended and carries higher bleeding risk 1

Special Considerations

If the patient has dysphagia or impaired swallowing:

• Deliver clopidogrel 75 mg plus aspirin 81 mg via enteral feeding tube, OR
• Use aspirin 325 mg rectal suppository as an alternative 1

If the patient is already on aspirin 81 mg daily:

• Give additional aspirin 160–325 mg as a one-time loading dose on Day 1 1
• Continue with the standard maintenance regimen thereafter 1